Becking G C
International Programme on Chemical Safety, World Health Organization, Research Triangle Park, NC 27709, USA.
Toxicol Lett. 1995 May;77(1-3):15-24. doi: 10.1016/0378-4274(95)03266-5.
Risk assessment (RA) for toxic chemicals is assumed to be a scientific activity providing a framework of principles for the complication and evaluation of all available scientific information and the rational extrapolation to human health effects in as quantitative terms as possible and with a high degree of certainty. Sensible public health decisions are made more certain through the use of mechanistic information throughout the 4 steps in RA: hazard identification, dose-response assessment, exposure (dose) assessment and risk characterisation. Examples of the use of mechanistic information to assess risks of systemic, developmental/reproductive and neurotoxic effects show how to move away from the presently used threshold/no observable adverse effect/uncertainty factor default methodology towards an evaluation based on all available scientific data. The experience gained in cancer RA in the use of metabolic and tissue binding (receptor) models as well as physiologically based pharmacokinetic (PBPK) and pharmacodynamic (PBPD) models can be transferred to non-cancer RA. A good example is the use of a PBPK model for the hepatoxicity of chloroform. As in cancer RA, as default positions are replaced by biological data the risk assessments become less uncertain when extrapolating between species. Combining information on tissue dosimetry and response data can also provide an estimate of variability within populations, which is impossible with present default type methodology but essential for adequate risk characterisation. Unlike the cancer field there is no single hypothesis for the mechanism of action for the multitude of non-cancer end-points studied.
有毒化学品的风险评估(RA)被认为是一项科学活动,它为整理和评估所有可用科学信息以及尽可能以定量方式并高度确定地合理推断对人类健康的影响提供了一个原则框架。在RA的四个步骤,即危害识别、剂量反应评估、暴露(剂量)评估和风险表征中,通过使用机制信息,明智的公共卫生决策变得更加确定。使用机制信息评估全身、发育/生殖和神经毒性作用风险的例子表明,如何从目前使用的阈值/无明显不良影响/不确定因素默认方法转向基于所有可用科学数据的评估。在癌症RA中使用代谢和组织结合(受体)模型以及基于生理学的药代动力学(PBPK)和药效学(PBPD)模型所获得的经验可以应用于非癌症RA。一个很好的例子是使用PBPK模型评估氯仿的肝毒性。与癌症RA一样,当默认立场被生物学数据取代时,在物种间进行推断时风险评估的不确定性就会降低。结合组织剂量学信息和反应数据还可以提供人群内变异性的估计,这是目前默认类型方法无法做到的,但对于充分的风险表征至关重要。与癌症领域不同的是,对于所研究的众多非癌症终点,没有单一的作用机制假设。